Probiodrug presented data on its pGlu-3 Abeta monoclonal Antibody at Neuroscience 2015, Chicago

Probiodrug presented data on its pGlu-3 Abeta monoclonal Antibody at Neuroscience 2015, Chicago ProbiodrugPosted on: 19 Oct 15   Probiodrug presented data on its pGlu-3 Abeta monoclonal Antibodyat Neuroscience 2015, Chicago Presentation at the Society for Neuroscience (SfN) Annual Meeting HALLE/SAALE, Germany, 19 October 2015 – Probiodrug AG (Euronext Amsterdam: PBD), a biopharmaceutical company developing novel therapeutic solutions to treat Alzheimer’s disease (AD), presented data on its specific pGlu3-Abeta monoclonal antibody at Neuroscience 2015, the 45 th annual meeting of the Society for Neuroscience (SfN) in Chicago, USA. The data presented result from a collaboration between Probiodrug and the research team led by Associate Professor Cynthia Lemere from the Center for Neurologic Diseases at the Brigham and Women’s Hospital and Harvard Medical School, Boston, MA. The oral presentation entitled “Preclinical in vivo…


Link to Full Article: Probiodrug presented data on its pGlu-3 Abeta monoclonal Antibody at Neuroscience 2015, Chicago